Contributed to the design and production of large-format exhibition graphics and digital assets for Merck’s Mavenclad and Rebif brands, both of which are treatments for multiple sclerosis (MS). Mavenclad is an oral medication for relapsing forms of MS, while Rebif is an injectable drug used to treat relapsing forms of MS by reducing the frequency of flare-ups.

The project involved experiential design elements, creating an engaging and immersive environment that facilitated meaningful interactions and showcased the brands’ contributions to MS treatment. This helped to enhance the overall attendee experience at ECTRIMS 2018 (European Committee for Treatment and Research in Multiple Sclerosis), a major international trade exhibition in Berlin.